Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
© 2024. The Author(s)..
Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB+ and CD8 proliferating proportions and a low Macro CD5L+ proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB+ and CD8 proliferating proportions are increased, but the CD8 GZMK+ proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB+ to CD8 GZMK+ facilitates good response to the therapy, while Macro CD5L+-CD8 GZMB+ crosstalk impairs the response by increasing CTLA4 in CD8 GZMB+. Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8+T-cell status conversion and exhaustion induced by Macro CD5L+ in influencing the response, suggesting future avenues for cancer treatment optimization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 20. Jan., Seite 621 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Jia-Cheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04ZR38536J |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 23.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-44795-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36736025X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36736025X | ||
| 003 | DE-627 | ||
| 005 | 20240123232023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-44795-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM36736025X | ||
| 035 | |a (NLM)38245530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Jia-Cheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB+ and CD8 proliferating proportions and a low Macro CD5L+ proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB+ and CD8 proliferating proportions are increased, but the CD8 GZMK+ proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB+ to CD8 GZMK+ facilitates good response to the therapy, while Macro CD5L+-CD8 GZMB+ crosstalk impairs the response by increasing CTLA4 in CD8 GZMB+. Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8+T-cell status conversion and exhaustion induced by Macro CD5L+ in influencing the response, suggesting future avenues for cancer treatment optimization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 650 | 7 | |a lenvatinib |2 NLM | |
| 650 | 7 | |a EE083865G2 |2 NLM | |
| 650 | 7 | |a CD5L protein, human |2 NLM | |
| 650 | 7 | |a Apoptosis Regulatory Proteins |2 NLM | |
| 650 | 7 | |a Receptors, Scavenger |2 NLM | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 700 | 1 | |a Wu, Lei-Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yi-Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xiao-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xiao-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Hai-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Xu-Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Yan-Zi |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Xian-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yi-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Peng-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Jia-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Zhen-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Guo-Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiao-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Qi-Man |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Ying-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Shuang-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Ke, Ai-Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Guo-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yi-Di |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Jia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 20. Jan., Seite 621 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:621 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-44795-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 20 |c 01 |h 621 | ||